Reforgene named a Future Healthcare Top 100 company for the fourth consecutive year
Recently, the 2026 Future Healthcare Top 100 conference hosted by VBDATA concluded successfully in Shanghai. The conference simultaneously released the authoritative "2026 Future Healthcare Top 100 (VB100)" series lists. Following consecutive listings from 2023 to 2025, Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene") once again entered the 2026 Innovative Medicine and Biologics TOP100, achieving its fourth consecutive listing. Four consecutive years of selection fully demonstrate Reforgene's deep accumulation and research strength in the innovative R&D of gene editing medicines, and represent the recognition by industry experts, industry observers and professional institutions of the company's technological barriers and innovative achievements.
With the theme of "Innovation, Trends, Synergy", this edition of the conference focused on frontier tracks including brain-computer interfaces, medical AI, synthetic biology, and the overseas expansion of pharmaceuticals and devices, bringing together heavyweight guests from government, academia, industry, investment and clinical fields to jointly explore the future development direction of China's healthcare industry.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.